Immunotherapy Medicines: A Reference Section, Not a Recommendation
This section explains named immunotherapy medicines used in cancer care — checkpoint inhibitors, biosimilars, and antibody-based and CAR-T therapies — in plain, sourced language. It exists to help patients, caregivers and referring clinicians understand what a medicine is and how it is evaluated, not to offer, price or recommend any specific medicine. For guidance on your own treatment, speak with your treating oncologist, or start with our immunotherapy overview.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
Why does CION publish pages about named immunotherapy medicines?
Patients and families searching for their diagnosis often land on the name of a medicine before they've spoken to an oncologist about it — a brand name from a relative's treatment, a news report, or a forum post. This section exists to give that search a sourced, plain-language, medically reviewed answer instead of an unverified one, without turning the answer into an advertisement.
Each page describes what a medicine is, the drug class it belongs to, its approved indications, sourced response-rate ranges with a date and a cited guideline body (NCCN, ASCO, ESMO, ICMR or CDSCO), and its current regulatory status in India — because approval and marketing status differ by medicine and change over time. No page in this section states that CION stocks, dispenses or administers a specific named medicine, and none carries a price against a molecule's name, a phone number, a WhatsApp link or a booking form.
How is the medicines section organized?
As pages are added, this section will grow into five areas. Each will link back here and to the immunotherapy pillar as it's published.
Checkpoint Inhibitor Medicines
PD-1, PD-L1 and CTLA-4 blocking medicines — for example nivolumab, pembrolizumab, atezolizumab, durvalumab and ipilimumab — explained by drug class, approved indications and sourced evidence.
Biosimilars, Pricing & Drug Authenticity
How biosimilar versions of checkpoint inhibitors are approved, published pricing context dated to its source, and how to check a product's authenticity and cold-chain handling.
Medicine Comparisons
Side-by-side comparisons of medicines within the same class or indication, set out as real tables — mechanism, approved use and evidence base, not a ranking of "better" or "best".
Antibody & Blood Cancer Medicines
Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates used in lymphoma and other blood cancers, explained alongside where they fit relative to chemotherapy.
CAR-T Products in India
CAR-T cell therapy products approved or in use in India, described for orientation only. CION does not administer CAR-T or stock CAR-T product — this section explains what it is and how referral to a CAR-T centre works.
Who this section is — and isn't — for
This section is for patients, caregivers and referring clinicians who want to understand what a named immunotherapy medicine is, how it works in general terms, and what published evidence and safety information say about it.
It is not: a price list; a place to buy, order or arrange a medicine; a substitute for your oncologist's advice; or a claim that any specific medicine suits your diagnosis, is stocked by CION, or will work for you. If you're looking for a cost estimate, a treatment schedule, or want to discuss whether a particular medicine could apply to your case, that conversation belongs with your treating oncology team — not this page.
Where does cost and availability information on these pages come from?
Where a medicine page mentions cost or availability, it cites a dated, published source — a manufacturer announcement, a regulatory filing, or reported news — never an unpublished figure or a CION rate card against a molecule's name. Two examples illustrate why dates matter here: a domestic biosimilar version of nivolumab launched in India in January 2026, at roughly a quarter of the reference product's price, after the original medicine's Indian patent lapsed in May 2026; pembrolizumab's patent protection, by contrast, is not expected to begin lapsing in India until around 2028-29. Figures like these move — always check the date on any figure you read, here or elsewhere.
Counterfeit checkpoint inhibitors have been reported entering the Indian market ahead of patent expiry on some products. This is a genuine patient-safety issue, not a scare tactic — the biosimilars and authenticity pages in this section will cover how genuine product is packaged, stored and verified.
Are all immunotherapy medicines approved for use in India?
No — approval and marketing status varies by medicine and by indication, and changes over time. Some checkpoint inhibitor, antibody-based or CAR-T medicines used elsewhere are approved in India for only certain cancers, are pending approval, or are not yet marketed here at all. Each medicine page in this section states the CDSCO approval and marketing position as understood at its own review date, and says so plainly when the position is genuinely unconfirmed rather than assuming either way.
Reading a Medicine Page on This Site
Why don't these pages show a price for a medicine?
Cost varies significantly by brand, biosimilar version, dose and negotiated hospital rates, and a published figure can go out of date within months. Where cost context is given, it cites a dated, published source — a manufacturer announcement, a regulatory filing, or reported news — never a CION rate card against a medicine's name. For a cost estimate for your own treatment, ask your treating hospital directly.
Does listing a medicine here mean it's available at CION?
No. Describing a medicine's approved use, evidence and safety profile is not the same as offering it. This section never states that CION stocks, dispenses or administers a specific named medicine. Whether a particular medicine forms part of your treatment is decided by your oncologist, based on your diagnosis, biomarker results, and the medicine's current approval and availability status.
Are these pages a recommendation to use a particular medicine?
No. Each page explains what a medicine is, how it is classed, sourced response-rate ranges, and its approved indications — never a personal recommendation or a claim that it will work for you. Only your treating oncologist, working from your own diagnosis and reports, can advise whether a specific medicine is appropriate.
How do I know if a medicine is approved for use in India?
Each medicine page states its current CDSCO approval and marketing status in India as of its own review date, because status can change. Some checkpoint inhibitor and antibody medicines are approved and marketed globally but not yet in India, or vice versa. Where the position is genuinely unclear at the time of writing, the page says so rather than assuming either way.
Who reviews these pages, and how often?
Every page in this section is medically reviewed and dated by a named medical oncologist from CION's panel, drawing on CDSCO status and guideline bodies such as NCCN, ASCO, ESMO and ICMR. Pages are revisited as approval status, biosimilar availability or guideline positions change — the "last reviewed" date at the top of each page tells you when that last happened.